Pharmasset, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 21   

Articles published

VRUS 0.0000
price chart
Undervalued Biotech Stocks Help Fund Beat the Index
Acker spent five years tracking the progress of a small biotech company called Pharmasset as it developed a promising new oral drug for hepatitis C and added it to his portfolio.
Related articles »  
Ralph Nader: The myths of corporate capitalism
Apple Inc. is spending $130 billion of its retained profits on a capital return program, $90 billion of which it will use to repurchase its own stock through 2015.
Cost of a cure: Popular hep C treatment costing $1000 a pill
But clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or a net margin of 56 percent. Two senators have ...
Health Highlights: July 29, 2014
Senators Ron Wyden (D-Ore) and Charles Grassley (R-Iowa) have asked maker Gilead Sciences Inc. to justify the cost of Sovaldi.
$1000 Sovaldi now hepatitis
But clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or a net margin of 56 percent.
$1000 Sovaldi now hepatitis treatment of choice
But clinical and commercial successes are also triggering scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, or a net margin of 56 percent. Two senators have ...
Related articles »  
$1000 pill now hepatitis C treatment of choice
But clinical and commercial successes have triggered scrutiny for the drug's manufacturer, California-based Gilead Sciences Inc., which just reported second-quarter profits of $3.66 billion, a net margin of 56 percent. Two senior senators are raising ...
Why Does Just One Of These Pills Cost $1000?  News One
$1000 Pill Now Leading Treatment for Hepatitis C  WebMD
Related articles »  
$1000-per-pill cure is difficult to swallow
John Milligan, Gilead Sciences Inc.'s president and chief operating officer, told financial analysts this month that Sovaldi is different from other drugs coming onto the market.
Gilead wins FDA approval of first cancer drug
The company has made several acquisitions over the past decade to expand into hepatitis, including the controversial $1,000-a-pill hepatitis C drug Sovaldi that it received in its $11 billion January 2011 acquisition of Pharmasset Inc. Gilead, led by ...
Gilead Sciences, Inc. (GILD), Apple Inc. (AAPL) and Twitter Inc (TWTR): Cramer ...
Gilead Sciences, Inc. (NASDAQ:GILD) bought Pharmasset, Inc. for $11 billion three years ago and with 89% premium which looked overpaid because the company had handful of assets with no real sales.
Latest Developments: Gilead Sciences Inc. (NASDAQ:GILD), StemCells Inc ...  Market News Call
Related articles »